Creative Planning
NERV icon

Creative Planning’s Minerva Neurosciences NERV Stock Holding History

Creative Planning’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-346
Closed -$33K – 4820
2016
Q4 		$33K Buy
+346
New +$35.3K ﹤0.01% 2724
2016
Q1 		– Sell
-38
Closed -$2K – 4459
2015
Q4 		$2K Buy
+38
New +$1.59K ﹤0.01% 4050

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Creative Planning's NERV Position: Q1 2017 in Review

Creative Planning sold out of Minerva Neurosciences (NERV) in Q1 2017, closing a stake of 346 shares — an estimated $33K sold.

Creative Planning first reported a position in NERV in Q4 2015 and held it in 2 quarters. The position peaked at $33K in Q4 2016. 71 funds tracked by Wall St. Rank hold NERV as of Q1 2017.

  • Creative Planning reported no remaining Minerva Neurosciences position as of Q1 2017 after selling out during the quarter.
  • Creative Planning sold 346 Minerva Neurosciences shares in Q1 2017, an estimated $33K.
  • Creative Planning first reported a position in Minerva Neurosciences in Q4 2015 and held it in 2 quarters.
  • Creative Planning's Minerva Neurosciences position peaked at $33K in Q4 2016.
  • 71 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q1 2017.

Based on Creative Planning's 13F filing for Q1 2017, filed 7 Apr 2017.